Top Markets
#1 Islamic Coin Islamic Coin +151.26%
#2 Akedo Akedo +76.66%
#3 Velvet Velvet +52.20%
#4 Glidr Glidr +51.75%
#5 DOVU DOVU +48.24%
#6 Black Phoenix Black Phoenix +33.87%
#7 Cross Cross +32.61%
#8 Cap Cap +20.07%
#9 DoubleZero DoubleZero +16.25%
#10 Movement Movement +9.75%
Coin of the day
Islamic Coin Islamic Coin
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.

HEPA
Classement en actions #39072
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is... Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Prix de l'action
$0.0568
Dernière synchronisation: 2026-08-13
Capitalisation boursière
$661.36K
Changement (1 jour)
11.37%
Changement (1 an)
-5.33%
Pays
US
Échange Hepion Pharmaceuticals, Inc. (HEPA)

Catégorie

Healthcare
Bénéfices pour Hepion Pharmaceuticals, Inc. (HEPA)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Hepion Pharmaceuticals, Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Hepion Pharmaceuticals, Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE